A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma

Inclusion criteria

• age of at least 18 years;
• Karnofsky Performance Status (KPS) ≥60;
• histologically confirmed nasopharyngeal squamous carcinoma;
• metastatic disease after primary standard treatment (patients who had metastatic diseases over six months after treatment);
• at least 1 measurable metastatic lesions in lung or mediastinal or pleura (imaging for distant metastases with FDG-PET/CT or chest/abdomen CT with contrast);
• adequate renal , liver and bone marrow function.

Exclusion criteria

• previous treatment with an immune checkpoint inhibitor;
• recurrent disease;
• previous systemic chemotherapy for metastatic disease;
• symptomatic central nervous system metastases;
• a history of non-infectious pneumonitis that required glucocorticoids, or active autoimmune disease;
• severe organ dysfunction or not suitable for chemoradiotherapy;
• individuals that had serious kidney, heart, blood, nervous system, or liver diseases or psychiatric disorders;
• individuals that had taken part in any other clinical trials testing other drugs within 3 months of the present study;
• other patients whom researchers deemed unsuitable to participate in the study.